Bromelain capped gold nanoparticles as the novel drug delivery carriers to aggrandize effect of the antibiotic levofloxacin

Authors

  • Paramdeep Bagga Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh 226026 (India)
  • Tarique Mahmood Ansari Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh 226026 (India)
  • Hefazat Hussain Siddiqui Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh 226026 (India)
  • Asad Syed Botany and Microbiology Department, Faculty of Science, King Saud University, Riyadh, Saudi Arabia
  • Ali H. Bahkali Botany and Microbiology Department, Faculty of Science, King Saud University, Riyadh, Saudi Arabia
  • Md. Azizur Rahman Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh 226026 (India)
  • Mohd. Sajid Khan Nanotechnology Lab, Department of Biosciences, Integral University, Lucknow, Uttar Pradesh 226026 (India)

DOI:

https://doi.org/10.17179/excli2016-710

Keywords:

antibacterial activity, bromelain, gold nanoparticles, levofloxacin, novel drug delivery carriers

Abstract

To develop bromelain capped gold nanoparticles (BRN capped Au-NPs) as the effective drug delivery carriers of the antibiotic levofloxacin (LvN) and evaluate antibacterial potential of its bioconjugated form compared to pure LvN. BRN capped Au-NPs were synthesized by in vitro method and bioconjugated to LvN using 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide as activator to form Au-BRN-LvN-NPs. These were characterized for mean particle size by dynamic light scattering analysis, zeta potential by Zetasizer nanosystem analysis and transmission electron microscopy (TEM) on carbon coated TEM copper grids by TEM respectively. Drug loading efficiency of LvN was calculated using UV-visible spectroscopy by standard curve of pure LvN. Antibacterial efficacy of Au-BRN-LvN-NPs and pure LvN was determined by evaluating minimum inhibitory concentration (MIC) against Staphylococcus aureus and Eschereschia coli. Two peaks were observed in Au-BRN-LvN-NPs spectrum one at 307 nm and other at 526 nm while one peak in BRN capped Au-NPs at 522 nm during UV spectroscopy suggesting red shift. The drug loading efficiency of LvN was found to be 84.8 ± 2.41 %. The diameter of Au-BRN-LvN-NPs and BRN capped Au-NPs were found to be (58.65 ± 2 nm, 38.11 ± 2 nm), zeta potential (-9.01 mV, -13.8 mV) and surface morphology (~13.2 nm, 11.4 nm) respectively. The MICs against S. aureus and E. coli were found to be (0.128 µg/mL, 1.10 µg/mL) for Au-BRN-LvN-NPs and (0.547 µg/mL, 1.96 µg/mL) for pure LvN. The results suggested that BRN capped Au-NPs can be used as effective drug delivery carriers of the antibiotic LvN. The Au-BRN-LvN-NPs exhibited enhanced antibacterial activity compared to pure LvN alone. (Graphical abstract see Figure 1)

Downloads

Published

2016-12-06

How to Cite

Bagga, P., Ansari, T. M., Siddiqui, H. H., Syed, A., Bahkali, A. H., Rahman, M. A., & Khan, M. S. (2016). Bromelain capped gold nanoparticles as the novel drug delivery carriers to aggrandize effect of the antibiotic levofloxacin. EXCLI Journal, 15, 772–780. https://doi.org/10.17179/excli2016-710

Issue

Vol. 15 (2016)

Section

Original articles

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).